We also observed several mutations in the MAP kinase signaling pathway (14% of tumors), involving KRAS, NRAS, BRAF, and MAP2K1 oncogenes across multiple cancer types including hematologic, lung, ovarian, duodenal, biliary, and colorectal (Figure 4, Table 2, Supplementary Table 7). The gene discussed is KRAS; the disease is cancer.